Tafasitamab plus lenalidomide as salvage therapy in diffuse large B-cell lymphoma: real-world experience from GELTAMO.

Gutierrez A, Zeberio I, Peñalver FJ, Martinez-Barranco P, Perez S, Morillo D, Martin X, Nicolas C, Ferrero A, Jimenez-Ubieto A, Bastos-Oreiro M, Davila-Valls J, Calle MV, Perez M, Rodriguez G, Alonso A, Garcia-Noblejas A, Sanchez Argüello D, Knight T, Fernandez Á, Lopez J, Perez De Oteyza J, González de Villambrosia S, Perez E, Marin A, Navarro MB, Fernandez R, Gomez P, Hueso JA, Peñarrubia Ponce MJ, Bravo P, Garcia-Belmonte D, De La Nuez H, Nistal S, Abrisqueta P, Ibañez F, Palomera L, Donato E, Provencio A, Infante MS, Gonzalez-Barca E

Open source

DOI
10.1182/bloodadvances.2025016661
Published
2025 Oct 14
Container
Blood advances
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1182/bloodadvances.2025016661,
  title = {Tafasitamab plus lenalidomide as salvage therapy in diffuse large B-cell lymphoma: real-world experience from GELTAMO.},
  author = {Gutierrez A and Zeberio I and Peñalver FJ and Martinez-Barranco P and Perez S and Morillo D and Martin X and Nicolas C and Ferrero A and Jimenez-Ubieto A and Bastos-Oreiro M and Davila-Valls J and Calle MV and Perez M and Rodriguez G and Alonso A and Garcia-Noblejas A and Sanchez Argüello D and Knight T and Fernandez Á and Lopez J and Perez De Oteyza J and González de Villambrosia S and Perez E and Marin A and Navarro MB and Fernandez R and Gomez P and Hueso JA and Peñarrubia Ponce MJ and Bravo P and Garcia-Belmonte D and De La Nuez H and Nistal S and Abrisqueta P and Ibañez F and Palomera L and Donato E and Provencio A and Infante MS and Gonzalez-Barca E},
  year = {2025},
  journal = {Blood advances},
  doi = {10.1182/bloodadvances.2025016661},
  url = {https://doi.org/10.1182/bloodadvances.2025016661}
}

RIS

TY  - JOUR
TI  - Tafasitamab plus lenalidomide as salvage therapy in diffuse large B-cell lymphoma: real-world experience from GELTAMO.
AU  - Gutierrez A
AU  - Zeberio I
AU  - Peñalver FJ
AU  - Martinez-Barranco P
AU  - Perez S
AU  - Morillo D
AU  - Martin X
AU  - Nicolas C
AU  - Ferrero A
AU  - Jimenez-Ubieto A
AU  - Bastos-Oreiro M
AU  - Davila-Valls J
AU  - Calle MV
AU  - Perez M
AU  - Rodriguez G
AU  - Alonso A
AU  - Garcia-Noblejas A
AU  - Sanchez Argüello D
AU  - Knight T
AU  - Fernandez Á
AU  - Lopez J
AU  - Perez De Oteyza J
AU  - González de Villambrosia S
AU  - Perez E
AU  - Marin A
AU  - Navarro MB
AU  - Fernandez R
AU  - Gomez P
AU  - Hueso JA
AU  - Peñarrubia Ponce MJ
AU  - Bravo P
AU  - Garcia-Belmonte D
AU  - De La Nuez H
AU  - Nistal S
AU  - Abrisqueta P
AU  - Ibañez F
AU  - Palomera L
AU  - Donato E
AU  - Provencio A
AU  - Infante MS
AU  - Gonzalez-Barca E
PY  - 2025
JO  - Blood advances
DO  - 10.1182/bloodadvances.2025016661
UR  - https://doi.org/10.1182/bloodadvances.2025016661
ER  -

APA

A, G., I, Z., FJ, P., P, M., S, P., D, M., X, M., C, N., A, F., A, J., M, B., J, D., MV, C., M, P., G, R., A, A., A, G., D, S. A., T, K., Á, F., J, L., J, P. D. O., S, G. D. V., E, P., A, M., MB, N., R, F., P, G., JA, H., MJ, P. P., P, B., D, G., H, D. L. N., S, N., P, A., F, I., L, P., E, D., A, P., MS, I., & E, G. (2025). Tafasitamab plus lenalidomide as salvage therapy in diffuse large B-cell lymphoma: real-world experience from GELTAMO.. Blood advances. https://doi.org/10.1182/bloodadvances.2025016661

Source records